Corient Capital Partners’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $492K | Buy |
2,411
+452
| +23% | +$92.2K | 0.04% | 341 |
|
|
2022
Q2 | $400K | Sell |
1,959
-391
| -17% | -$79.8K | 0.03% | 398 |
|
|
2022
Q1 | $495K | Buy |
2,350
+593
| +34% | +$125K | 0.03% | 390 |
|
|
2021
Q4 | $421K | Sell |
1,757
-776
| -31% | -$186K | 0.03% | 407 |
|
|
2021
Q3 | $717K | Sell |
2,533
-411
| -14% | -$116K | 0.05% | 277 |
|
|
2021
Q2 | $1.02M | Buy |
2,944
+254
| +9% | +$87.9K | 0.07% | 211 |
|
|
2021
Q1 | $753K | Buy |
2,690
+360
| +15% | +$101K | 0.06% | 238 |
|
|
2020
Q4 | $570K | Sell |
2,330
-1,397
| -37% | -$342K | 0.06% | 253 |
|
|
2020
Q3 | $1.06M | Sell |
3,727
-58
| -2% | -$16.4K | 0.12% | 155 |
|
|
2020
Q2 | $1.01M | Buy |
3,785
+893
| +31% | +$239K | 0.12% | 155 |
|
|
2020
Q1 | $915K | Buy |
2,892
+176
| +6% | +$55.7K | 0.14% | 133 |
|
|
2019
Q4 | $806K | Sell |
2,716
-2,637
| -49% | -$783K | 0.1% | 204 |
|
|
2019
Q3 | $1.25M | Buy |
5,353
+3,367
| +170% | +$784K | 0.18% | 137 |
|
|
2019
Q2 | $465K | Buy |
1,986
+626
| +46% | +$147K | 0.07% | 248 |
|
|
2019
Q1 | $321K | Buy |
1,360
+153
| +13% | +$36.1K | 0.05% | 273 |
|
|
2018
Q4 | $363K | Buy |
1,207
+422
| +54% | +$127K | 0.06% | 239 |
|
|
2018
Q3 | $277K | Hold |
785
| – | – | 0.05% | 235 |
|
|
2018
Q2 | $228K | Buy |
+785
| New | +$228K | 0.04% | 247 |
|
|
2017
Q3 | – | Sell |
-935
| Closed | -$254K | – | 272 |
|
|
2017
Q2 | $254K | Sell |
935
-52
| -5% | -$14.1K | 0.04% | 275 |
|
|
2017
Q1 | $270K | Buy |
987
+70
| +8% | +$19.1K | 0.04% | 265 |
|
|
2016
Q4 | $260K | Buy |
+917
| New | +$260K | 0.05% | 269 |
|